National Coverage Analysis (NCA)

Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration

CAG-00066R4

Expand All | Collapse All

Contacts

Lead Analysts
Kimberly Long
kimberly.long@cms.hhs.gov
410-786-5702
Chuck Shih
Lead Medical Officers
James Rollins, MD

History of Considerations

History Title ID
Original Consideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066N View
First reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R View
Second reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R2 View
Third reconsideration Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration CAG-00066R3 View
Fourth reconsideration Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration CAG-00066R4 You are here